Pitfalls in MLH1 promoter methylation assessment, including POLEmut/MLH1meth endometrial adenocarcinoma
Pathology - Research and Practice · 2026
DOI: 10.1016/j.prp.2025.156303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Amelia Flaus und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Division of Pathology, Unity Health Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: MutL Protein Homolog 1, Endometrial Neoplasms, DNA Methylation, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
MLH1 promoter methylation status may serve as an important diagnostic, prognostic, and predictive biomarker in management of mismatch repair (MMR)-deficient cancers. A new commercial assay for detection of MLH1 promoter hyper-methylation (EntroGen), which interrogates regions C and D, was assessed for its performance characteristics. False positive results were obtained in 5/21 non-lesional cases, with signals limited to region C. Three were explained by overloaded reactions. Two unexplained cases were both muscle samples (2/6 muscle samples, one each of skeletal and smooth). The assay was 100 % concordant (52/52) for lesional samples with expected MLH1 promoter methylation status. These included two exceptional cases-one Lynch-associated, and one POLE-mutated endometrial carcinoma; thus expanding the spectrum of extreme cases, and demonstrate neither germline or somatic NGS results completely rule out MLH1 promoter methylation, and vice versa. The POLEmut/MLH1meth carcinoma was notable for molecular features in keeping with POLE dysfunction, accompanied by multiple, additional genetic lesions in the MMR pathway. Exploring the TCGA dataset, 1/8 cases of POLE (ultramutated) endometrial carcinoma was notable for MLH1 silencing. Comprehensive genomic profiling assay was informative, allowing for correlation of MLH1 methylation and POLE genotype results with tumor mutation burden and mutational signature. Taken together, our data highlight the need for integrated approach in endometrial carcinoma biomarker testing, integrating NGS and MLH1 promoter methylation status, the latter of which benefits from assessing both regions C and D. Finding of MLH1 promoter methylation does not rule out either Lynch syndrome or ultramutated (POLE) carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Division of Pathology, Unity Health Toronto, Toronto, ON, Canada.
- Department of Laboratory Medicine, North York General Hospital, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Department of Laboratory Medicine, Division of Pathology, Unity Health Toronto, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; D…
Zitieren
APA
Flaus, A., Cui, Z., Miladinovic, M., & Yoon, J. Y. (2026). Pitfalls in MLH1 promoter methylation assessment, including POLEmut/MLH1meth endometrial adenocarcinoma. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156303
Vancouver
Flaus A, Cui Z, Miladinovic M, Yoon JY. Pitfalls in MLH1 promoter methylation assessment, including POLEmut/MLH1meth endometrial adenocarcinoma. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2025.156303
BibTeX
@article{Flaus2026,
author = {Flaus, Amelia and Cui, Zhi and Miladinovic, Mirko and Yoon, Ju-Yoon},
title = {Pitfalls in MLH1 promoter methylation assessment, including POLEmut/MLH1meth endometrial adenocarcinoma},
journal = {Pathology - Research and Practice},
year = {2026},
doi = {10.1016/j.prp.2025.156303}
}
EUVIMED